ErbB Family of Receptor Tyrosine Kinases in Cancer and Drug Therapy
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 30 November 2025 | Viewed by 16
Special Issue Editors
Interests: EGFR; lung cancer; tyrosine kinase inhibitors; monoclonal antibodies; drug resistance
Special Issues, Collections and Topics in MDPI journals
Interests: cancer biology; STAT3; signal transduction; chemoresistance; immunotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The ErbB family of receptor tyrosine kinases (RTKs) includes the epidermal growth factor receptor (EGFR) or ErbB1/Her1, ErbB2/Her2, ErbB3/Her3, and ErbB4/Her4. These RTKs are key regulators of physiological processes, such as cell growth, survival, and differentiation. Dysregulation of ErbB receptors is implicated in the development and progression of many types of cancers, making them targets for therapeutic strategies. This Special Issue will focus on the latest advancements in understanding the molecular mechanisms underlying the role of ErbB family members in tumorigenesis, and the development of novel therapeutic strategies targeting these receptors. In addition to therapeutic approaches, we will also address the challenge of resistance to ErbB-targeted therapies and explore strategies to overcome this resistance, including combination approaches. Original research articles and reviews exploring both basic and clinical research are welcome.
Dr. Ilaria Marrocco
Dr. Donatella Romaniello
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- ErbB
- RTKs
- EGFR
- HER2
- HER3
- cancer
- targeted therapies
- drug resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
